Genomic Biomarkers Market by Application (Oncology, Cardiovascular Diseases, and Neurological Diseases); and End User (Diagnostic & Research Laboratories and Hospitals) - Global Opportunities and Industry Forecasts, 2018-2025

Get 20% Free Customization In This Report

Diagnostics and Biotech	LI_184141	Pages: NA	May 2019 \| 676 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Biomarkers are minimally or non-invasive tools used in imaging technology to provide clear imaging of oncology tumors & other problems and also eliminate the chance of radiation exposure during imaging through CT scans and MRI scans. Genomic biomarkers are used to test high blood pressure, hyperkalemia, and other monogenic conditions. They reflect the expression of a gene, function of a gene, and regulation of a gene in normal biologic processes, pathogenic processes, and responses to therapeutics.

The major factors that contribute to the growth of the genomic biomarkers market include increasing prevalence of ovarian, gastric, and colorectal cancers, high demand for minimally invasive procedures, development of technologies in clinical laboratory tests, immense developments in infrastructure for data sharing and analysis such as bioinformatics, and growing awareness about genomics biomarker-based personalized medicines.

However, complex processes associated with genomics biomarker and stringent government regulations hamper the growth of the global genomic biomarkers market. Growing awareness about the role of biomarkers to diagnose fatal diseases such as cancer and cardiovascular diseases & reimbursement issues are being solved with the intervention of regulatory authorities, which is expected to propel the growth of the market in the near future.

The global genomic biomarkers market is segmented on the basis of application, end user, and region. On the basis of application, the market is segmented into oncology, cardiovascular diseases, neurological diseases, and others. On the basis of end user, the market is segmented into diagnostic & research laboratories, hospitals, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Aepodia SA, Myriad Genetics, Inc., Eurofins Scientific, QIAGEN, Bio-Rad Laboratories, Inc., Genomic Health, Liquid Genomics, Epigenomics AG, and AROS Applied Biotechnology A/S.

Key Benefits

The study provides an in-depth analysis of the global genomic biomarkers market with current trends and future estimations to elucidate imminent investment pockets.
The report provides information about the current and upcoming trends in the global genomic biomarkers market from 2016 to 2023, which helps determine prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the global genomic biomarkers market has been provided.
Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global genomic biomarkers market.

Genomic Biomarkers Market Key Segments:

By Application

Oncology
Cardiovascular diseases
Neurological diseases
Others

By End User

Diagnostic and research laboratories
Hospitals
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GENOMIC BIOMARKERS MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLOGY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CARDIOVASCULAR DISEASES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. NEUROLOGICAL DISEASES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 GENOMIC BIOMARKERS MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. DIAGNOSTIC & RESEARCH LABORATORIES

5.2.1. Market size and forecast

5.3. HOSPITALS

5.3.1. Market size and forecast

Chapter: 6 GENOMIC BIOMARKERS MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America genomic biomarkers market by application
6.2.5. North America genomic biomarkers market by end user

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe genomic biomarkers market by application
6.3.5. Europe genomic biomarkers market by end user

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific genomic biomarkers market by application
6.4.5. Asia-Pacific genomic biomarkers market by end user

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA genomic biomarkers market by application
6.5.5. LAMEA genomic biomarkers market by end user

Chapter: 7 COMPANY PROFILES

7.1. THERMO FISHER SCIENTIFIC INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. F. HOFFMANN-LA ROCHE AG

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. AEPODIA SA

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. MYRIAD GENETICS, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. EUROFINS SCIENTIFIC

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. QIAGEN

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. BIO-RAD LABORATORIES, INC.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. GENOMIC HEALTH

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. EPIGENOMICS AG

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. AROS APPLIED BIOTECHNOLOGY A/S

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Genomic Biomarkers Market by Application (Oncology, Cardiovascular Diseases, and Neurological Diseases); and End User (Diagnostic & Research Laboratories and Hospitals) - Global Opportunities and Industry Forecasts, 2018-2025